Nuwellis (NUWE)
NASDAQ:NUWE
Want to see NUWE full AI Analyst Report?
NUWE Stock Chart & Stats
$1.76
-$0.08(-7.15%)
At close: 4:00 PM EST
$1.76
-$0.08(-7.15%)
Day’s Range― - ―
52-Week Range$0.13 - $25.95
Previous CloseN/A
Volume102.02K
Average Volume (3M)289.18K
Market Cap
$1.79M
Enterprise Value-$1.12M
Total Cash (Recent Filing)$2.08M
Total Debt (Recent Filing)$265.00K
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Aug 11, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-64.02
Shares Outstanding12,750,321
10 Day Avg. Volume82,161
30 Day Avg. Volume289,177
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.58
Price to Sales (P/S)1.45
P/FCF Ratio-1.10
Enterprise Value/Market Cap-0.63
Enterprise Value/Revenue-0.13
Enterprise Value/Gross Profit-0.20
Enterprise Value/Ebitda0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.69
Revenue Forecast (FY)$9.01M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 65-70% indicate the Aquadex platform and consumables have attractive unit economics. Durable gross-profitability provides room to absorb sales/service investments and, with scale, can convert into operating leverage that supports sustained cash-flow improvement over months to years.
Pediatric Commercial TractionStrong and growing pediatric adoption demonstrates product-market fit in a specialized, high-trust segment. A concentrated installed base at leading hospitals supports recurring consumables pull-through, lowers marginal sales costs, and builds clinical credibility that should sustain adoption and recurring revenue over the medium term.
Acquisition Broadens Clinical PlatformAdding RendiaTech expands Nuwellis from fluid removal into kidney monitoring and decision support, creating a more integrated cardiorenal offering. This strategic product breadth can increase clinical value, stickiness, and cross-sell potential, supporting structural differentiation versus single-product competitors.
Bears Say
Persistent Cash BurnMulti-year negative operating and free cash flow at this scale relative to current revenue creates ongoing runway pressure and reliance on external financing. Unless monthly burn falls per management targets or revenue scales rapidly, cash constraints will force dilution, reduced investment, or disruptive cost cuts that impair long-term execution.
Large Operating Losses And Rising ExpensesOperating expenses materially exceed current revenue, producing deep losses that negate high gross margins. Sustained elevated SG&A and sales costs without commensurate scale risk a prolonged path to profitability; management must demonstrably control fixed costs or substantially grow revenue to reach sustainable margins.
RendiaTech Commercialization Timing RiskThe acquired kidney-monitoring product's multi-quarter development and 2027 U.S. target delay anticipated synergies and revenue diversification. This timing risk means expected incremental value won't alleviate near-term burn, increasing execution risk and dependence on achieving cost reductions before new product revenue materializes.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $0.13 and its highest was $25.95 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is $1.79M.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Aug 11, 2026 which is in 58 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on May 12, 2026. The company reported -$2.09 earnings per share for the quarter, missing the consensus estimate of -$1 by -$1.09.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Overvalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate is -0.68.
How many shares outstanding does Nuwellis have?
Nuwellis has 12,750,321 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -$2.09 in its last earnings report, missing expectations of -$1. Following the earnings report the stock price went down -0.962%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuwellis
Nuwellis, Inc. is a medical device firm specializing in the creation, production, and commercialization of devices for ultrafiltration therapy. Its primary offerings, the Aquadex FlexFlow and Aquadex SmartFlow systems, are specifically designed to address fluid overload in patients who have not responded adequately to diuretic medications. The Aquadex FlexFlow system, for instance, consists of a main console, a single-use blood circuit, and a catheter. The company distributes its solutions to hospitals and clinics through its dedicated salesforce within the United States. Internationally, its products are available via a network of independent specialty distributors in numerous countries, including Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. Founded in 1999, and based in Eden Prairie, Minnesota, the company adopted the name Nuwellis, Inc. in April 2021, having previously operated as CHF Solutions, Inc.
NUWE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple positive operational and strategic developments (notably 26% revenue growth, a 70.1% gross margin, pediatric adoption, the RendiaTech acquisition, a new patent, leadership and board strengthening, and a ~$5M capital infusion). However, notable challenges remain: a ~$4.3M net loss, operating expenses up ~46%, modest cash on hand (~$2.2M), and a multi-quarter timeline to commercialize RendiaTech's target product. On balance, the highlights indicate meaningful early execution progress and strategic positioning, but the company must deliver on its burn reduction and commercialization milestones to sustain momentum.View all NUWE earnings summariesNUWE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―
Ownership Overview
8.63% Insiders
0.11% Mutual Funds
1.85% Other Institutional Investors
89.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---